Company Overview
Cibus, Inc. operates as an agricultural biotechnology firm dedicated to the development and licensing of gene-edited plant traits designed to enhance agricultural productivity and sustainability. Within the broader Healthcare sector, the company specifically functions in the Biotechnology industry, focusing on delivering solutions that enable farmers to achieve higher yields while reducing reliance on chemical inputs such as fungicides, insecticides, and fertilizers. The organization currently maintains a market capitalization of $203.11M and employs a workforce of 118 individuals to execute its strategic objectives. These valuation figures indicate that the company is a mid-sized entity within its niche, operating with a significant gap between its market capitalization and its reported annual revenue of $3.64M, which is typical for biotechnology firms that carry substantial research and development costs not yet reflected in bottom-line profitability. The disparity between the $203.11M market cap and the $3.64M revenue suggests that the market is pricing in future potential or asset value rather than current cash flow generation, a common characteristic in the biotech sector where intellectual property and pipeline assets hold significant weight.
Financial Health
The company reported a revenue of $3.64M over the trailing twelve-month period, yet it posted a net income of $-127,085,000, creating a stark contrast that reveals a highly aggressive cost structure or significant impairment charges typical of early-stage biotechnology ventures. This negative net income contrasts sharply with the reported EBITDA of $-61,541,000, highlighting that non-cash expenses or specific accounting adjustments are driving the bottom-line loss beyond the level of cash-based operational earnings. Free cash flow stands at $-51,790,624, indicating that the company is burning through capital reserves to fund its operations and development programs, which limits immediate financial flexibility and necessitates a reliance on external financing or existing cash balances. The gross margin is listed at 100.0%, which is structurally common for biotechnology companies that sell licensed traits or intellectual property where the cost of goods sold is negligible compared to the revenue generated from licensing agreements. However, the operating margin of -1273.3% and profit margin of 0.0% demonstrate severe operational inefficiencies relative to revenue or substantial one-time costs that have eroded profitability. The balance sheet shows a cash position of $9.92M against total debt of $267.96M, resulting in a debt-to-equity ratio of 1227.56, which signifies an extremely leveraged position where debt obligations vastly exceed liquid assets. The current ratio of 0.72 further underscores potential short-term liquidity constraints, as the company's current assets are insufficient to cover its current liabilities without additional financing. Return on Equity is -221.0% and Return on Assets is -12.9%, metrics that reveal that management is currently generating negative returns on the capital invested by shareholders and the asset base, reflecting the high-risk nature of the current business phase.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of positive earnings, while the forward P/E is -14.35, implying that expected future earnings are also projected to be negative or that the market is utilizing alternative metrics to gauge value in the absence of traditional profitability. The price-to-book ratio stands at 7.14, indicating that the market values the company at a significant premium over its net book value, likely reflecting the perceived worth of its gene-editing patents and future commercialization potential. The price-to-sales ratio is 55.82, and the EV/EBITDA is -7.42; these alternative metrics suggest that investors are willing to pay a high multiple for every dollar of sales despite the company's current inability to generate earnings or positive cash flow from operations. The stock trades between a 52-week high of $4.19 and a 52-week low of $1.09, with the current price trading in the lower portion of this range relative to the historical volatility observed over the past year. The beta value of 1.75 indicates that the stock's price volatility is significantly higher than the broader market, moving more than 75% more than the average market index during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is -12.8%, while earnings growth is N/A, indicating that the company is currently contracting in terms of top-line sales rather than expanding its revenue base. The absence of positive earnings growth combined with the decline in revenue suggests that the company is struggling to scale its licensing agreements or maintain sales momentum in its existing markets. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company reinvests its limited earnings or capital into growth initiatives rather than distributing income to shareholders, a strategy necessitated by its negative net income and high debt obligations. The overall growth and income profile is characterized by a contraction in sales, negative earnings, and no dividend distribution, reflecting a high-risk, capital-intensive phase typical of a biotechnology company with substantial debt and negative free cash flow.